Decision to operate on hepatocellular cancer patients is not driven by comorbidities in Louisiana.

 0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Denise Danos, John Lyons, Mary Maluccio, Lauren Maniscalco, Omeed Moaven, Annie Talbot, Xiao-Cheng Wu, Yong Yi

Ngôn ngữ: eng

Ký hiệu phân loại: 373.236 Lower level

Thông tin xuất bản: England : HPB : the official journal of the International Hepato Pancreato Biliary Association , 2025

Mô tả vật lý:

Bộ sưu tập: NCBI

ID: 644096

 BACKGROUND: The mortality rate of Hepatocellular cancer (HCC) in Louisiana is second worst in the United States. This has been linked to underutilization of curative treatment (CT). This study aimed to identify risk factors associated with underutilization of CT in Louisiana. METHODS: Patients with AJCC T1 HCC diagnosed from 2011 to 2020 were identified from the Louisiana Tumor Registry (LTR) using site and histology codes. Patients who underwent CT (ablation, resection, and transplantation) were compared to those who did not undergo CT. Logistic regression was performed and results reported as adjusted odds ratios. RESULTS: CT was utilized in 462 (37 %) of 1247 patients with T1 HCC. There were no significant differences observed in age, race, BMI, poverty, or rurality between CT and non-CT patients. The percentage of cirrhosis was similar in both groups (35.3 % vs. 37.7 %, NS). On multivariant analysis, lack of CT was independently associated with low socioeconomic status (SES
  p = 0.040), treatment outside a COC center (p <
  0.001), and lack commercial/private insurance (p <
  0.001). CONCLUSION: Utilization of CT is driven not by comorbidities, but by insurance type, low SES, and treatment facility indicating the profound effect that care disparities have on HCC treatment.
Tạo bộ sưu tập với mã QR

THƯ VIỆN - TRƯỜNG ĐẠI HỌC CÔNG NGHỆ TP.HCM

ĐT: (028) 36225755 | Email: tt.thuvien@hutech.edu.vn

Copyright @2024 THƯ VIỆN HUTECH